NEW YORK (GenomeWeb) – Luminex reported after the close of the market on Monday that its third quarter revenues were down 2 percent year over year, driven in part by a delay in the timing of customer orders that closed a few days after the end of the quarter.

For the quarter ended Sept. 30, the molecular diagnostics company reported revenues of $72.4 million, down from $74.1 million in the year-ago quarter, and short of the average Wall Street estimate for revenues of $74.1 million.